Ultragenyx Pharmaceutical Inc.’s Revenue Growth at a glance
Ultragenyx Pharmaceutical Inc. reports revenue growth of 29% for Dec 2024. The prior period recorded 19.5% (Dec 2023). Year over year the metric moved +9.5 pts (+48.6%). The rolling three-period average stands at 17.3%. Data last refreshed Dec 7, 2025, 2:55 AM.
Latest reading
29% · Dec 2024
YoY movement
+9.5 pts (+48.6%)
Rolling average
17.3%
Current Revenue Growth
29%
+9.5 pts
+48.6%
Rolling average
17.3%
Latest Value
29%
Dec 2024
YoY Change
+9.5 pts
Absolute
YoY Change %
+48.6%
Rate of change
3-Period Avg
17.3%
Smoothed
Narrative signal
Ultragenyx Pharmaceutical Inc.’s revenue growth stands at 29% for Dec 2024. Year-over-year, the metric shifted by +9.5 pts, translating into a +48.6% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How revenue growth shapes Ultragenyx Pharmaceutical Inc.'s story
As of Dec 2024, Ultragenyx Pharmaceutical Inc. reports revenue growth of 29%. Evaluate revenue acceleration, seasonality, and long-term expansion for U.S. equities using annual growth data.
How to read revenue growth
Consistent double-digit revenue growth typically indicates demand strength and market share gains. Sharp decelerations may point to competitive or macro headwinds.
Balancing growth with profitability
Growth only creates value when paired with improving margins or cash generation. Pair revenue growth with profitability metrics to judge overall health.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
86.3%
Operating Margin
-95.7%
Net Profit Margin
-101.6%
Return on Equity
-222.9%
Return on Assets
-37.9%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Ultragenyx Pharmaceutical Inc. (RARE) FAQs
Answers tailored to Ultragenyx Pharmaceutical Inc.’s revenue growth profile using the latest Financial Modeling Prep data.
What is Ultragenyx Pharmaceutical Inc.'s current revenue growth?
As of Dec 2024, Ultragenyx Pharmaceutical Inc. reports revenue growth of 29%. This reading reflects the latest filings and price data for RARE.
How is Ultragenyx Pharmaceutical Inc.'s revenue growth trending year over year?
Year-over-year, the figure shifts by +9.5 pts (+48.6%). Pair this context with revenue growth and free cash flow signals to gauge momentum for RARE.
Why does revenue growth matter for Ultragenyx Pharmaceutical Inc.?
Revenue growth measures the percentage change in top-line sales compared with the prior period. For Ultragenyx Pharmaceutical Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Ultragenyx Pharmaceutical Inc.'s revenue growth above its recent average?
Ultragenyx Pharmaceutical Inc.'s rolling three-period average sits at 17.3%. Comparing the latest reading of 29% to that baseline highlights whether momentum is building or fading for RARE.
How frequently is Ultragenyx Pharmaceutical Inc.'s revenue growth refreshed?
Data for RARE was last refreshed on Dec 7, 2025, 2:55 AM and updates automatically every 24 hours, keeping your valuation inputs current.